Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.51 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378765 | 0.87 | POLB (0.65) | POLBMAPTHPGDSMN1; SMN2MEN1 | |
| SCHEMBL5373250 | 0.86 | POLB (0.63) | POLBMCL1MAPK1MAPTMEN1 | |
| SCHEMBL12598081 | 0.86 | POLB (0.73) | POLBMAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14435102 | 0.86 | POLB (0.57) | POLBMCL1MAPK1MAPTGFER | |
| SCHEMBL5376605 | 0.85 | POLB (0.65) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12597593 | 0.85 | POLB (0.72) | POLBMAPTSMN1; SMN2GPR27ALDH1A1 | |
| SCHEMBL5391332 | 0.84 | POLB (0.61) | POLBMCL1MAPK1MAPTGFER | |
| SCHEMBL5380381 | 0.84 | POLB (0.61) | POLBMAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13313580 | 0.83 | ALDH1A1 (0.62) | POLBMCL1MAPTHPGDGFER | |
| SCHEMBL27680073 | 0.83 | POLB (0.60) | POLBMCL1MAPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | GOETZE LEOPOLD F | 2007-10-04 | — | — | US | disclosed |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | GOETZE LEOPOLD F | 2007-10-04 | — | — | US | disclosed |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | GOETZE LEOPOLD F | 2007-10-04 | — | — | US | disclosed |
| EP-1765320-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | Pfizer Products Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005115369-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | PPARG, PPARD, PPARA | POLB 3078/4885MCL1 4288/4885MAPK1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.